Project UpdateJun 4, 2026, 07:01 AM
AEON Biopharma Presents Data Supporting ABP-450 Biosimilarity to BOTOX®
AI Summary
AEON Biopharma announced the presentation of new analytical and functional data at the American Headache Society's 68th Annual Scientific Meeting, supporting the biosimilarity of ABP-450 to BOTOX®. The data demonstrated highly similar biological activity across multiple analytical approaches, including LC-MS peptide mapping and the LD50 potency assay, with ABP-450 lots meeting predefined equivalence criteria. This strengthens the analytical foundation for ABP-450, which targets the over $3.0 billion U.S. therapeutic neurotoxin market, where BOTOX® is currently the sole approved treatment for chronic migraine.
Key Highlights
- AEON Biopharma presented new analytical and functional data for ABP-450 at the 68th Annual Scientific Meeting of the American Headache Society.
- The data supports the biosimilarity of ABP-450 to BOTOX® (onabotulinumtoxinA) for therapeutic use.
- Highly similar biological activity was demonstrated across genomic sequence alignment, LC-MS peptide mapping, and LD50 potency assay.
- LC-MS peptide mapping showed 93%-99% sequence coverage with no variant peptides between ABP-450 and BOTOX®.
- All ABP-450 lots in the LD50 potency assay met predefined equivalence criteria established from BOTOX® reference results.
- BOTOX® is currently the only botulinum toxin therapy approved for chronic migraine, a major therapeutic indication.
- The U.S. therapeutic neurotoxin market exceeds $3.0 billion annually, representing a significant opportunity.
Price Impact
More from AEON